| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01859637 Details | 2016-03-28 Interventional | 4 | 6 | Lenograstim Neutropenia Severe Chronic … | Additional pharmacovigilance activity was considered as fulfilled by the EMA. This was an Additional Pharmacovigilance Activity (MEA005). Based on interim study data, complemented with clinical data from continued global development & extensive post-marketing experience MEA005 was considered fulfilled and the study terminated. | |||
| NCT01212094 Details | 2016-03-28 Interventional | 1/2 | [1 Refs] | 44 | Rituximab Multiple Sclero… Multiple Sclero… Sclerosis | The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial The trial was closed prematurely for futility, because pre-determined interim analysis demonstrated that selected dosing led to <50% depletion of B cells from the brain/spinal cord. Therefore, only 5 patients per group finished trial. | ||
| NCT00286403 Details | 2016-03-28 Interventional | 2/3 | 0 | Fenoldopam Acute Kidney In… Acute Renal Fai… | The study was terminated due to logistics at a local hospital. - | |||
| NCT00652093 Details | 2016-03-25 Interventional | 4 | 24 | Acetaminophen Acetaminophen, … Dextropropoxyph… Levopropoxyphen… Oxymorphone Constriction, P… Spinal Stenosis Lumbar Spinal S… | Removal of Darvocet from US market This study terminated early (leading to small number of subjects analyzed) due to US Food and Drug Administration (FDA) removing active control (Darvocet) from the U.S. market. | |||
| NCT01930292 2012-003676-40 Details | 2016-03-24 Interventional | 1 | 31 | Carboplatin Paclitaxel Solid Tumors | Part B was cancelled based on business decision - | |||
| NCT01545635 Details | 2016-03-23 Interventional | 3 | 100 | Thrombin Blood Coagulati… Hemostatic Diso… Wounds and Inju… Major Trauma | The Interim analysis (100 patients) revealed a possible harm to patients randomised to the
fresh frozen plasma (FFP) treatment arm. - | |||
| NCT01329744 Details | 2016-03-23 Interventional | 1 | 16 | Mecasermin Lipodystrophy Metabolic Disea… HIV Lipodystrop… | - - | |||
| NCT00573157 Details | 2016-03-23 Interventional | 2/3 | 6 | Mycophenolic Ac… Lupus Nephritis Nephritis | The study was terminated due to unanticipated safety issues The study was terminated due to unanticipated safety issues. | |||
| NCT02426164 Details | 2016-03-22 Interventional | 4 | 0 | Bupivacaine Epinephrine Methylprednisol… Morphine Pain, Postopera… Arthroplasty, R… Osteoarthritis | Could not receive facility approval - | |||
| NCT00947895 Details | 2016-03-22 Interventional | 2/3 | 30 | Adrenocorticotr… Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Multiple Sclero… Recurrence Sclerosis | Study reached halfway point in approximately one year time period and was halted to analyze
data. - | |||
| NCT00580216 2007-004817-33 Details | 2016-03-21 Interventional | 3 | [1 Refs] | 3773 | Biotin Idrabiotaparinu… Idraparinux Warfarin Atrial Fibrilla… Thromboembolism | early discontinuation based on strategic sponsor decision not driven by any safety concern - | ||
| NCT02713139 Details | 2016-03-18 Interventional | 3 | 0 | Clotrimazole Metronidazole Miconazole Vaginal Dischar… Sexual Active W… | Due to budget limitations, the company decided to withdraw this study. - | |||
| NCT02711241 Details | 2016-03-17 Interventional | 3 | 15 | Dipyrone Papaverine Gastroenteritis | Not enough patients - | |||
| NCT01737892 Details | 2016-03-17 Interventional | 1/2 | 21 | Epinephrine Epinephryl bora… Racepinephrine Asthma | unable to validate analytical method - | |||
| NCT01518153 Details | 2016-03-17 Interventional | 2 | 16 | Alemtuzumab Fludarabine Fludarabine pho… Melphalan Methotrexate Tacrolimus Myeloproliferat… Leukemia Lymphoma Myeloma Myeloproliferat… | Objectives not met. - | |||
| NCT01069796 Details | 2016-03-17 Interventional | 2 | 64 | Bevacizumab Capecitabine Paclitaxel Breast Neoplasm… Triple Negative… | The number of inclusion was reached normally - | |||
| NCT00522249 Details | 2016-03-17 Interventional | 1/2 | 10 | Erlotinib Hydro… Interferon-alfa… Interferon-alph… Interferons Peginterferon a… Sunitinib Carcinoma Carcinoma, Rena… | PI decision - | |||
| NCT00521274 Details | 2016-03-17 Interventional | 2 | 11 | Docetaxel Prostatic Neopl… | Oxford BioMedica halted TroVax injections - | |||
| NCT00450008 Details | 2016-03-17 Interventional | 2 | 9 | Docetaxel Thalidomide Prostatic Neopl… | PI decision - | |||
| NCT00447473 Details | 2016-03-17 Interventional | 2 | 31 | Ketoconazole Mitoxantrone Prostatic Neopl… | PI decision - |